Novo Nordisk’s Ozempic receives EMA’s nod for chronic kidney disease treatment
HQ Team December 13, 2024: Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
Health
Rosuvastatin may lower mortality compared to atorvastatin: Study
HQ Team November 9, 2024: A recent study indicates that rosuvastatin is associated with a slightly reduced risk of all-cause mortality and major.
Drugs
Health
Medical
One-third of West Africans have gene variants causing kidney disease
Researchers have found genomic variants in one-third of people from the West African countries of Ghana and Nigeria that significantly increase the risk.
Drugs
Health
Pharma
AstraZeneca acquires France’s Amolyt Pharma for $1.05 billion
British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.
Drugs
Health
Pharma
Novo’s end-stage hypertension trial drug fails, $817m impairment loss
Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss.
Drugs
Health
Medical
Vitamin D deficiency linked to cardiovascular, CKD morbidity
HQ Team May 20, 2024: Vitamin D deficiency is associated with poor outcomes in cardiovascular diseases and chronic kidney disease (CKD) in patients with early-stage.
Drugs
Health
Pharma
Novo Nordisk says Ozempic reduces kidney disease progression
HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney deaths in 24%.
Drugs
Health
Pharma
Novo Nordisk to buy hypertension drug from KBP for $1.3 billion
HQ Team October 16, 2023: Danish pharmaceutical company, Novo Nordisk, announced it was buying a hypertension drug, still in trials, from Singapore-based KBP.